BioSpace News Archive

Lexicon Pharmaceuticals, Inc., announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.

Telix Pharmaceuticals Limited today announced highly positive top-line results from the pivotal Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, NCT03849118) of its investigational renal (kidney) cancer positron emission tomography (PET) imaging agent, TLX250-CDx (89Zr-DFO-girentuximab). The study has met its co-primary and secondary endpoints.

Ascletis Pharma Inc. announces that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis has been reported at The Liver Meeting® 2022 of the American Association for the Study of Liver Diseases as poster presentation.